secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001104659-26-010036
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem reports preliminary 2025 product revenue $30.9M; cash runway to H1 2027
--------------------------------------------------------------------------------

- Preliminary AVMAPKI FAKZYNJA CO-PACK net revenue: Q4 2025 ~$17.5M, full year 2025 ~$30.9M (launch from May 2025).
- Cash, equivalents, investments $205M at Dec 31, 2025; pro-forma $234M netting $29.4M from warrant exercises.
- Anticipates LGSOC commercial launch and development to be self-sustaining by 2H 2026.
- VS-7375 KRAS G12D inhibitor: interim Phase 1/2 update in 1H 2026; FDA discussions on registration-directed trials planned.
- RAMP 205 PDAC expansion cohort update with ≥6 months follow-up expected in Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465926010036/0001104659-26-010036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465926010036/tm265057d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-010036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer